Effect of asthma and asthma medication on the prognosis of patients with COVID-19

Choi, Young Jun; Park, JuYoung; Lee, Hye Sun; Suh, Jin Suck; Song, Jeung Yoon; Byun, Min Kwang; Cho, Jae Hwa; Kim, Hyung Jung; Lee, Jae Hyun; Park, Jung-Won; Park, Hye Jung

doi:10.1183/13993003.02226-2020

Cited by 122 publications

(134 citation statements)

References 29 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…A systematic literature review finds that there was no significant difference in the combined risk of requiring admission to ICU and/or receiving mechanical ventilation for people with asthma (RR 0.87, 95% CI 0.94-1.37) and risk of death from Covid-19 (RR 0.87; 95% CI 0.68-1.10) [38].These findings are similar to the ones conducted in another meta-analysis [40,41]. Overall, the literature suggests that asthma is not an independent risk factors for the clinical outcomes of Covid-19 [36]. In a study by Chibba et al [42], asthma was not associated with an increased risk of hospitalization (relative risk, 0.96; 95% CI, 0.8-1.2) after adjusting for age, sex, and comorbidities.…”

Section: Covid-19 and Asthmasupporting

confidence: 76%

“…As in the rest of the cases, a strand of the literature has focused on estimating the prevalence of asthma among Covid-19 patients. In a study in South Korea, the prevalence of asthma among Covid-19 patients was 2.9% [36], somewhat similar to another review which finds that asthma is a pre-morbid condition in about 1.6% of the Covid-19 patients [37]. Another systematic review of the link between asthma and Covid-19 finds a somewhat higher prevalence of asthma among Covid-19 patients (7.46%) [38] echoing the heterogeneity of prevalence across different countries and regions as reported in another systematic review [39].…”

Section: Covid-19 and Asthmamentioning

confidence: 98%

See 1 more Smart Citation

Covid-19 and non-communicable diseases: evidence from a systematic literature review

Nikoloski

Alqunaibet²,

Alfawaz³

et al. 2021

BMC Public Health

111

View full text Add to dashboard Cite

Background Since early 2020, the Covid-19 pandemic has engulfed the world. Amidst the growing number of infections and deaths, there has been an emphasis of patients with non-communicable diseases as they are particularly susceptible to the virus. The objective of this literature review is to systematize the available evidence on the link between non-communicable diseases and Covid-19. Methods We have conducted a systematic review of the literature on Covid-19 and non-communicable diseases from December, 2019 until 15th of November, 2020. The search was done in PubMed and in doing so we used a variety of searching terms in order to isolate the final set of papers. At the end of the selection process, 45 papers were selected for inclusion in the literature review. Results The results from the review indicate that patients with certain chronic illnesses such as diabetes, hypertension (and other cardiovascular diseases), chronic respiratory illnesses, chronic kidney and liver conditions are more likely to be affected by Covid-19. More importantly, once they do get infected by the virus, patients with chronic illnesses have a much higher likelihood of having worse clinical outcomes (developing a more severe form of the disease or dying) than an average patient. There are two hypothesized channels that explain this strong link between the chronic illnesses enumerated above and Covid 19: (i) increased ACE2 (angiotensin-converting enzyme 2) receptor expressions, which facilitates the entry of the virus into the host body; and (ii) hyperinflammatory response, referred to as “cytokine storm”. Finally, the literature review does not find any evidence that diabetes or hypertension related medications exacerbate the overall Covid-19 condition in chronic illness patients. Conclusions Thus, the evidence points out to ‘business as usual’ disease management model, although with greater supervision. However, given the ongoing Covid-19 vulnerabilities among people with NCDs, prioritizing them for the vaccination process should also figure high on the agenda on health authorities.

show abstract

Section: Covid-19 and Asthmasupporting

confidence: 76%

Section: Covid-19 and Asthmamentioning

confidence: 98%

Covid-19 and non-communicable diseases: evidence from a systematic literature review

Nikoloski

Alqunaibet²,

Alfawaz³

et al. 2021

BMC Public Health

111

View full text Add to dashboard Cite

show abstract

“…Although there are some differences among studies, the use of asthma medication (inhaled or systemic corticosteroids and biologics), and asthma severity were not independent factors for poor clinical outcomes of COVID-19 [ 1 , 2 , 12 ]. In our experience there was no relationship between disease severity (established according to the treatment prescribed) and symptoms.…”

Section: Discussionmentioning

confidence: 99%

Symptoms in patients with asthma infected by SARS-CoV-2

García-Pachón

Ruiz-Alcaraz

Baeza-Martínez

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

Introduction Organ tropism of SARS-CoV-2 to the respiratory tract could potentially aggravate asthma. The susceptibility of patients with asthma to develop an exacerbation when they are infected with SARS-CoV-2 is unknown. We aimed to investigate the symptoms presented in patients with asthma who became infected with SARS-CoV-2. Methods and Results All patients over 14 years of age who tested positive for SARS-CoV-2 (by RT-PCR) were included (n=2,995). In patients with asthma (n=77, 2.6%; 44 females), symptoms, therapy and phenotype were recorded. Seventeen (22%) patients had mild asthma, 55 (71%) moderate and five severe (6%). Twenty-six patients with asthma (34%) were asymptomatic, 34 (44%) developed symptoms but did not require hospital admission, and 17 (22%) were hospitalised. One patient was admitted because of asthma exacerbation without pneumonia or other symptoms. Ten patients (13%) had wheezes (six with pneumonia). Comparison of wheezing between patients with non-T2 asthma and the rest of the patients was statistically significant, ( p <0.001). Conclusions SARS-CoV-2 infection is not a significant cause of asthma exacerbation, although some patients may present wheezing, especially in cases of pneumonia. The severity of asthma does not seem to be associated with symptoms of the disease.

show abstract

“…Study subjects. HIRA released, via an online portal (accessible at https ://hira-covid 19.net), de-identified records for 7590 patients who were confirmed to be infected with COVID-19 by a reverse transcription polymerase chain reaction test for SARS-CoV-2 using nasopharyngeal swab or sputum specimens 10 . Further data linked to all of the claim records of these COVID-19 patients since January 2017 were provided from the HIRA database.…”

Section: Methodsmentioning

confidence: 99%

Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea

Lee

Son

Han

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Underlying chronic respiratory disease may be associated with the severity of coronavirus disease 2019 (COVID-19). This study investigated the impact of chronic obstructive pulmonary disease (COPD) on the risk for respiratory failure and mortality in COVID-19 patients. A nationwide retrospective cohort study was conducted in 4610 patients (≥ 40 years old) infected with COVID-19 between January 20 and May 27, 2020, using data from the Ministry of Health and Welfare and Health Insurance Review and Assessment Service in Korea. The clinical course and various clinical features were compared between COPD and non-COPD patients, and the risks of respiratory failure and all-cause mortality in COPD patients were analyzed using a multivariate logistic regression model. Among 4610 COVID-19 patients, 4469 (96.9%) and 141 (3.1%) were categorized into the non-COPD and COPD groups, respectively. The COPD group had greater proportions of older (≥ 60 years old) (78.0% vs. 45.2%, P < 0.001) and male (52.5% vs. 36.6%, P < 0.001) patients than the non-COPD group. Relatively greater proportions of patients with COPD received intensive critical care (7.1% vs. 3.7%, P = 0.041) and mechanical ventilation (5.7% vs. 2.4%, P = 0.015). Multivariate analyses showed that COPD was not a risk factor for respiratory failure but was a significant independent risk factor for all-cause mortality (OR = 1.80, 95% CI 1.11–2.93) after adjustment for age, sex, and Charlson Comorbidity Index score. Among COVID-19 patients, relatively greater proportions of patients with COPD received mechanical ventilation and intensive critical care. COPD is an independent risk factor for all-cause mortality in COVID-19 patients in Korea.

show abstract

Effect of asthma and asthma medication on the prognosis of patients with COVID-19

Cited by 122 publications

References 29 publications

Covid-19 and non-communicable diseases: evidence from a systematic literature review

Covid-19 and non-communicable diseases: evidence from a systematic literature review

Symptoms in patients with asthma infected by SARS-CoV-2

Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea

Contact Info

Product

Resources

About